Related references
Note: Only part of the references are listed.Sodium-glucose co-transporter-2 inhibitors and epicardial adiposity
Habib Yaribeygi et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2023)
Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment
Subramanian Boopathi et al.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2021)
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
Yihai Liu et al.
LIPIDS IN HEALTH AND DISEASE (2021)
Flavonoids against the SARS-CoV-2 induced inflammatory storm
Alena Liskova et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu et al.
THERANOSTICS (2021)
A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function
Habib Yaribeygi et al.
ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS (2020)
The reproductive number of COVID-19 is higher compared to SARS coronavirus
Ying Liu et al.
JOURNAL OF TRAVEL MEDICINE (2020)
Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: A mechanistic review
Habib Yaribeygi et al.
LIFE SCIENCES (2020)
COVID-19 and the cardiovascular system
Ying-Ying Zheng et al.
NATURE REVIEWS CARDIOLOGY (2020)
Neuromodulatory effects of anti-diabetes medications: A mechanistic review
Habib Yaribeygi et al.
PHARMACOLOGICAL RESEARCH (2020)
U1 snRNP regulates cancer cell migration and invasion in vitro
Jung-Min Oh et al.
NATURE COMMUNICATIONS (2020)
Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms
Abdul Mannan Baig et al.
ACS CHEMICAL NEUROSCIENCE (2020)
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhuo Zhou et al.
CELL HOST & MICROBE (2020)
COVID-19, Arrhythmic Risk, and Inflammation Mind the Gap!
Pietro Enea Lazzerini et al.
CIRCULATION (2020)
Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics
Ernesto Maddaloni et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2020)
Diabetes is a risk factor for the progression and prognosis of COVID-19
Weina Guo et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2020)
Guidelines for the management of diabetes services and patients during the COVID-19 pandemic
G. Rayman et al.
DIABETIC MEDICINE (2020)
COVID-19 and immunomodulation in IBD
Markus F. Neurath
GUT (2020)
Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19
Mark A. Marinella
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2020)
Pericytes, inflammation, and diabetic retinopathy
Benjamin G. Spencer et al.
INFLAMMOPHARMACOLOGY (2020)
COVID-19 and diabetes: Is there enough evidence?
Marijana Tadic et al.
JOURNAL OF CLINICAL HYPERTENSION (2020)
World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)
Catrin Sohrabi et al.
INTERNATIONAL JOURNAL OF SURGERY (2020)
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes
Carmen Hierro-Bujalance et al.
ALZHEIMERS RESEARCH & THERAPY (2020)
Diabetes and COVID-19
Zachary T. Bloomgarden
JOURNAL OF DIABETES (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Real estimates of mortality following COVID-19 infection
David Baud et al.
LANCET INFECTIOUS DISEASES (2020)
COVID-19 cytokine storm: the interplay between inflammation and coagulation
Ricardo J. Jose et al.
LANCET RESPIRATORY MEDICINE (2020)
Could SARS-CoV-2-Induced Hyperinflammation Magnify the Severity of Coronavirus Disease (CoViD-19) Leading to Acute Respiratory Distress Syndrome?
A. S. Smiline Girija et al.
FRONTIERS IN IMMUNOLOGY (2020)
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus
Habib Yaribeygi et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2020)
Managing Hyperglycemia in the COVID-19 Inflammatory Storm
Roma Gianchandani et al.
DIABETES (2020)
SGLT2 inhibition and COVID-19: The road not taken
Liza Das et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2020)
The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients
Shubham Soni et al.
CANADIAN JOURNAL OF CARDIOLOGY (2020)
Management of diabetes in patients with COVID-19
Jean-Daniel Lalau et al.
Lancet Diabetes & Endocrinology (2020)
Immune Response, Inflammation, and the Clinical Spectrum of COVID-19
Luis F. Garcia
FRONTIERS IN IMMUNOLOGY (2020)
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial
Spyridon G. Deftereos et al.
JAMA NETWORK OPEN (2020)
Cytokine storm induced by SARS-CoV-2
Peipei Song et al.
CLINICA CHIMICA ACTA (2020)
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology perspective on current knowledge
Sambit K. Mohanty et al.
DIAGNOSTIC PATHOLOGY (2020)
SGLT-2 inhibitors as cardioprotective agents in COVID-19
Kashish Gupta et al.
HEART & LUNG (2020)
Coronavirus infection (SARS-CoV-2) in obesity and diabetes comorbidities: is heat shock response determinant for the disease complications?
Mauricio Krause et al.
DIABETOLOGY & METABOLIC SYNDROME (2020)
Anti-inflammatory properties of antidiabetic drugs: A promised land in the COVID-19 era?
Niki Katsiki et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
Inflammation: A bridge between diabetes and COVID-19, and possible management with sitagliptin
Negin Mozafari et al.
MEDICAL HYPOTHESES (2020)
Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib
Sarah C. Gruenert et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Diabetes, infection risk and COVID-19
Suheda Erener
MOLECULAR METABOLISM (2020)
Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression
Jesus Beltran-Garcia et al.
ANTIOXIDANTS (2020)
The Impact of Diabetes Mellitus in COVID-19: A Mechanistic Review of Molecular Interactions
Habib Yaribeygi et al.
JOURNAL OF DIABETES RESEARCH (2020)
An Immediate and Long-Term Complication of COVID-19 May Be Type 2 Diabetes Mellitus: The Central Role of β-Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms
Melvin R. Hayden
CELLS (2020)
COVID-19 and diabetes mellitus: An unholy interaction of two pandemics
Rimesh Pal et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
Hongyi Li et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Miriam Merad et al.
NATURE REVIEWS IMMUNOLOGY (2020)
The trinity of COVID-19: immunity, inflammation and intervention
Matthew Zirui Tay et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys
Habib Yaribeygi et al.
DRUG DISCOVERY TODAY (2019)
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira et al.
DRUGS (2019)
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
Hiddo J. L. Heerspink et al.
DIABETOLOGIA (2019)
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Carlo Garofalo et al.
MEDICINA-LITHUANIA (2019)
Hyperglycemia acts in synergy with hypoxia to maintain the pro-inflammatory phenotype of macrophages
Mangesh Morey et al.
PLOS ONE (2019)
The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus
Weiling Leng et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
Francesca Iannantuoni et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition
Elodie M. Varin et al.
CELL METABOLISM (2019)
A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Sodium-glucose cotransporter inhibitors and oxidative stress: An update
Habib Yaribeygi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Golnaz Ranjbar et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis
Ting Yuan et al.
REDOX BIOLOGY (2019)
Development of SGLT1 and SGLT2 inhibitors
Timo Rieg et al.
DIABETOLOGIA (2018)
Hyperglycemia Affects the Expression of Inflammatory Genes in Peripheral Blood Mononuclear Cells of Patients with Type 2 Diabetes
Mohamad Akbari et al.
IMMUNOLOGICAL INVESTIGATIONS (2018)
Inflammation of brown/beige adipose tissues in obesity and metabolic disease
F. Villarroya et al.
JOURNAL OF INTERNAL MEDICINE (2018)
Vitamin D supplementation for improvement of chronic low-grade inflammation in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Aya Mousa et al.
NUTRITION REVIEWS (2018)
Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
Hao Zhou et al.
REDOX BIOLOGY (2018)
Hyperglycemia induces inflammatory mediators in the human chorionic villous
Simone Correa-Silva et al.
CYTOKINE (2018)
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
F. Bonnet et al.
DIABETES & METABOLISM (2018)
Recent novel approaches to limit oxidative stress and inflammation in diabetic complications
Raelene J. Pickering et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2018)
The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet
Ji Hye Han et al.
DIABETOLOGIA (2017)
Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice
Farhana Naznin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Oxidative Stress, Inflammation, and Vascular Aging in Hypertension
Tomasz J. Guzik et al.
HYPERTENSION (2017)
Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice
Eveliina Munukka et al.
ISME JOURNAL (2017)
Inflammatory responses and inflammation-associated diseases in organs
Linlin Chen et al.
Oncotarget (2017)
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Sebastian Steven et al.
REDOX BIOLOGY (2017)
Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)
Mihoko Matsumura et al.
DIABETES THERAPY (2017)
Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM)
Mihoko Matsumura et al.
DIABETES THERAPY (2017)
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Liang Xu et al.
EBIOMEDICINE (2017)
Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality
Taichi Sugizaki et al.
NPJ AGING AND MECHANISMS OF DISEASE (2017)
Circulating IL-8 levels are increased in patients with type 2 diabetes and associated with worse inflammatory and cardiometabolic profile
F. A. Cimini et al.
ACTA DIABETOLOGICA (2017)
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study
Fumika Shigiyama et al.
CARDIOVASCULAR DIABETOLOGY (2017)
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
Michael Joubert et al.
DIABETES (2017)
Obesity and inflammation: the linking mechanism and the complications
Mohammed S. Ellulu et al.
ARCHIVES OF MEDICAL SCIENCE (2017)
Hyperglycemia, tumorigenesis, and chronic inflammation
Shu-Chun Chang et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications
Caroline Pereira Domingueti et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-A2-Glycoprotein Levels in Patients with Type 2 Diabetes
Xin Liao et al.
SCIENTIFIC REPORTS (2016)
Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice
Takashi Hatanaka et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2016)
Prevention of oxidative stress, inflammation and mitochondrial dysfunction in the intestine by different cranberry phenolic fractions
Marie-Claude Denis et al.
CLINICAL SCIENCE (2015)
Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
A. Ojima et al.
HORMONE AND METABOLIC RESEARCH (2015)
The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
Matthias Oelze et al.
PLOS ONE (2014)
Sodium Glucose Co-Transporter 2 Inhibitors and Their Mechanism for Improving Glycemia in Patients With Type 2 Diabetes
Jaime A. Davidson et al.
POSTGRADUATE MEDICINE (2014)
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-α in LLC-PK1 cells
M. I. Maldonado-Cervantes et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2012)
Share Paper
